The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual JP Morgan Healthcare Conference in San Francisco
Biocon Biologics will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual JP Morgan Healthcare Conference in San Francisco.
The company is set to unveil three new biosimilar oncology assets—Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda)—at the 2026 JP Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. This will enable the company to broaden the availability of critical oncology therapies through cost‑effective biosimilar alternatives. Global sales of Keytruda were $29.5 billion in 2024; Opdivo sales in 2024 were $9.3 billion; and Herceptin SC and Herceptin HYLECTA combined sales were $1.72 billion in 2024. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which includes Pertuzumab (Perjeta) that was recently submitted to the FDA, as well as several small molecule cancer therapies. The company’s oncology portfolio, including undisclosed products, represents an over $75 billion opportunity, or approximately 35 per cent of the global oncology pharmaceutical market.
Shreehas Tambe, CEO and Managing Director, Biocon Biologics, said, “At the 2026 JP Morgan Healthcare Conference, we will share how our integration with Biocon Limited strengthens Biocon Biologics’ ability to deliver both biosimilars and generics at global scale. This will position us to better serve patients across diabetes, oncology, and immunology, including expanding access to biosimilar insulins and generic GLP‑1 peptides amid the rising diabetes and obesity burden. Guided by a science‑led, R&D approach, we are advancing a strong pipeline with 17 oncology assets to meet varied patient needs. These efforts underscore our commitment to providing affordable, high‑quality medicines for patients around the world.”
